Evaluation of Lipid Profile Changes in Pediatric Patients with Acute Mononucleosis

Shirin Sayyahfar¹, Amin Lavasani², Alireza Nategian¹, and Abdollah Karimi³

¹Department of Pediatrics, Division of Pediatric Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran; ²Pediatrician, Bahman Hospital, Zanjan, Iran; ³Pediatric Infections Research Center, Mofid Children’s Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Background: Acute Epstein–Barr virus (EBV) infection could lead to atherogenic lipid profile changes in adults; while there is no evidence about the children with Infectious mononucleosis (IM). The aim of this study was to evaluate the lipid profile of the children in acute phase of mononucleosis and two months after the recovery.

Materials and Methods: From 2010 through 2012, 36 children with IM aged 1-10 years were enrolled in a prospective cross-sectional study. Fasting serum total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), and triglyceride level were measured during acute phase of the disease and after 2 months of the recovery.

Results: From 36 patients enrolled, 25 (69.4%) cases were male and the mean age of the patients was 4.1 ± 2.0 years. The mean of the total cholesterol level in the acute phase and 2 months after the recovery were 149.5 ± 35.3 mg/dL and 145.7 ± 30.6, respectively (P = 0.38). However, the serum level of HDL cholesterol in patients after 2 months of recovery was significantly increased (37.9 ± 9.3 mg/dL vs. 28.5 ± 10.6 mg/dL, P <0.001). The mean value of serum LDL cholesterol was significantly reduced, two months after recovery (81.4 ± 19.5 mg/dL, vs. 92.6 ± 28.8 mg/dL, P = 0.009). Furthermore, the serum triglyceride level was significantly reduced after the recovery (108.7 ± 36.9 mg/dL) compared with the acute phase (163.8 ± 114.3 mg/dL) (P = 0.004).

Conclusion: EBV infection in children could change lipid profile which is partially restored 2 months after the recovery.

Key Words: Atherogenic changes; Epstein–Barr virus; Infectious mononucleosis; Lipid profile; Pediatrics

Introduction

Several studies have indicated that atherosclerosis in adults begins from childhood [1]. The etiology of this phenomenon is multifactorial; the type of the diet, life style, genetic tendency and some underling diseases (e.g. diabetes, hypertension) are known predisposing factors. In addition, infectious diseases especially chronic and recurrent ones (e.g periodontitis) might be the other reason of atherosclerosis [1].

Infection with microorganisms such as Chlamydia pneumoniae, and cytomegalovirus, has been shown to increase the incidence of coronary artery disease (CAD), and these microor-
organisms have been detected in atherosclerotic plaques [2]. In
addition, infections not directly related to vessels wall such as
Heli
cobacter pylori and Herpes simplex virus infections; chronic
bronchitis, and chronic dental infections, are also associated
with increased incidence of CAD [2-4].

The changes seen during these infections include a reduc-
tion in the total cholesterol, high density lipoprotein (HDL),
low-density lipoprotein (LDL), Apolipoprotein A-I, Apolipo-
protein B and lipoprotein a (LP a) levels [3]. The increased
level of triglyceride and Apo-lipoprotein E has also been docu-
mented in these infections [3]. It is reported that in some infec-
tions with microorganisms such as HIV, the level of small
dense LDL, which has a greater atherogenic properties com-
pared with LDL, increases in and in some other infections (e.g.
brucellosis) would not reach its normal level even after four
months of the recovery [5, 6].

Infections also produce alterations in the composition and
function of lipoproteins [7, 8]. The existing evidences suggest
that change in lipoproteins level during infection is a part of
acute phase response of innate immune system [6].

Increase in total triglycerides, triglyceride rich lipoproteins,
small dense LDL, the activity of platelet activating factor acetyl
hydrolase, sphingolipid rich lipoproteins, as well as HDL de-
crease are the changes which can lead to atherogenesis.

Besides, HDL metabolism alteration during infection results
in a reduction of the HDL abilities in protection against athero-
genesis through antioxidant and reverse cholesterol transport
mechanisms. Such changes can explain the correlation of in-
flammation and infection with atherogenesis [9]. In addition,
response to infection and inflammation increases the amount
of oxidized lipids in serum, and induces LDL oxidation in the
body.

Enhancement of LDL oxidation during infection and inflam-
ination may cause atherogenesis, and can be a mechanism for
the increase of coronary artery diseases in patients with chronic
infection and inflammatory diseases [2].

Epstein-Barr virus (EBV) infection causes infectious mono-
nucleosis, the most common symptoms of which are fever,
pharyngitis, lymphadenopathy and organomegaly [10].

According to the findings of a study on adult patients, acute
EBV infection could change the lipid profile which predisposes
patients to atherogenesis [9]. However there is no supportive
evidence of these changes among pediatric patients with acute
infectious mononucleosis. The present study was conducted to
evaluate the changes in serum lipid of pediatric patients with
acute infectious mononucleosis and to compare them with the
results obtained two months afterward. As far as we are aware,
the current study is the first research on the lipid profile chang-
es in acute EBV infection in children.

Materials and Methods

This prospective cross-sectional study was conducted from
2010 through 2012 at Ali Asghar Children’s Hospital, Tehran,
Iran. The study was approved by the local ethics review com-
mitee for clinical research and informed consent was received
from the children’s guardians before enrollment. Thirty six Pa-
tients between 1-10 years old with acute EBV infection, visited
or admitted in the hospital, were enrolled in this study in a
sequential manner.

The definite diagnosis of acute EBV infection in clini-
cal-based suspected cases was carried out via laboratory tests
of positive anti-EBV (IgM and/or IgG anti VCA Ab) and nega-
tive EBV antinuclear antibody (EBNA). Patients with, underly-
ing liver and renal diseases, malignancy, hypo- or hyperthy-
roidism, sever failure to thrive (FTT), and patients treated with
drugs affecting the serum lipid profile, were excluded from this
study.

The age, gender and clinical manifestations of patients with
acute EBV infection, including fever, lymphadenopathy, phar-
yngitis, and organomegaly, were recorded in a checklist for
each patient. Fasting venous blood samples were collected to
analyze the lipid profile level, including serum total cholesterol,
HDL and LDL cholesterol, and triglyceride levels. The blood
samples were collected at the peak of the symptoms in the
acute phase of the disease, as soon as the EBV infection was
confirmed, regardless of the hospital admission or in the out-
patient set up. Based on a study of serum lipid profiles in Irani-
ian children by Azizi et al., and the guidelines of United States
National Cholesterol Education Program (NCEP), total chole-
sterol level less than 170 mg/dL, between 170-199 mg/dL and
more than 200 mg/dL were considered as desirable, at moder-
ate risk, and high risk, respectively [11-13]. Also, LDL choles-
terol levels less than 110 mg/dL, between 110-130 mg/dL, and
more than 130 mg/dL were considered as desirable, moderate
and high risk, respectively. Given the 10th percentile, the lower
limit of HDL cholesterol level in Iranian children was consid-
ered 40 mg/dL. Regarding to the patients’ age and gender, a se-
rum triglyceride level less than the 90th percentile was consid-
ered in normal range. Thus, in boys and girls aging 1-4 years
the triglyceride levels less than 85 mg/dL and 95 mg/dL and in
5-10 years, less than 70 mg/dL and 103 mg/dL were considered
as normal, respectively [11].
Two months after the recovery, the measurement of lipid profile of the cases was repeated. The descriptive statistics, including frequencies, means and standard deviations were measured; the data were categorized to desirable and undesirable lipid profile categories according to the references [11-13], and were presented as numbers and percentages. As the data was related, for comparing lipid profile categories between baseline and two months later, Wilcoxon signed ranks test was performed. P-values less than 0.05 were considered as statistically significant. The relationship between lipid profile changes and acute phase values was evaluated using Pearson correlation test.

Results

Out of 36 children with infectious mononucleosis, 25 (69.4%) cases were male. The mean age of the patients was 4.1 ± 2.0 years (from 1 to 10 years) and 22 (61.1%), and 14 (38.9%) of them were within 1 to 5, and 6 to 10 years age groups, respectively. The body mass index (BMI) of all cases was within normal range and none of them was overweight or obese. Also none of them had family history of documented hyperlipidemia.

The most common clinical manifestations were fever (100%); exudative pharyngitis (55.6%) and cervical lymphadenopathy (52.8%). The frequency of the other manifestations is shown in Table 1.

The mean serum total cholesterol level of the patients was 149.5 ± 35.3 mg/dL in the acute phase of the disease. Twenty-six cases (72.2%) had serum cholesterol level lower than 170 mg/dL and 4 patients (11.1%) had serum cholesterol level higher than 200 mg/dL. The mean serum total cholesterol level was 145.7 ± 30.6 mg/dL after 2 months of the recovery, which showed no statistically significant difference with the acute phase of the disease (P = 0.38).

Whereas the amount of serum HDL cholesterol revealed a significant increase 2 months after the recovery compared to the acute phase of the disease (37.9 ± 9.3 mg/dL vs. 28.5 ± 10.6 mg/dL, respectively P < 0.001). In the acute phase, 31 (86.1%) patients had HDL levels lower than 40 mg/dL; while after 2 months of the recovery, 20 (55.5%) cases showed serum HDL level lower than 40 mg/dL (P = 0.004) (Table 2).

In addition, the mean value of serum LDL significantly decreased 2 months after the recovery compared with the acute phase of the disease (84.1 ± 19.5 mg/dL vs. 92.6 ± 28.8 mg/dL, respectively, P = 0.009).

Serum triglyceride levels also decreased substantially after the recovery (108.7 ± 36.9 mg/dL vs. 163.8 ± 114.3 mg/dL, respectively, P = 0.004) (Table 2).

The Lipid profile in children with infectious mononucleosis showed no correlation with the age of the patients in acute phase and after the recovery (P ≥0.19). Moreover, there was no

Table 1. Frequency of signs and symptoms of the patients with acute infectious mononucleosis

| Signs and symptoms    | EBV positive (n = 36) |
|-----------------------|-----------------------|
| Fever                 | 36 (100%)             |
| Exudative pharyngitis | 20 (55.6%)            |
| Lymphadenopathy       | 19 (52.8%)            |
| Splenomegaly          | 11 (30.6%)            |
| Hepatomegaly          | 7 (19.4%)             |
| Rash                  | 1 (2.8%)              |
| Seizure               | 1 (2.8%)              |

EBV, Epstein–Barr virus.

Table 2. Lipid profile of patients with acute infectious mononucleosis at the acute phase and two months after the recovery

|                         | Acute phase of infection (n = 36) | 2 months after recovery (n = 36) | P-value |
|-------------------------|-----------------------------------|---------------------------------|---------|
| Total cholesterol (mg/dL)| Normal (<170)                      | 26 (72.2%)                      | 28 (77.7%) | 0.16    |
|                         | Moderate risk (170-199)            | 6 (16.6%)                       | 6 (16.6%) | 0.68    |
|                         | High risk (>200)                   | 4 (11.1%)                       | 2 (5.5%)  | 0.32    |
| HDL-cholesterol (mg/dL) | Normal (>40)                       | 5 (13.8%)                       | 16 (44.4%) | 0.001   |
|                         | Decreased (<40)                    | 31 (86.1%)                      | 20 (55.5%) | 0.08    |
| LDL-cholesterol (mg/dL) | Normal (<110)                      | 28 (77.7%)                      | 32 (88.8%) | 0.08    |
|                         | Moderate risk (110-129)            | 6 (16.6%)                       | 4 (11.1%)  | 0.32    |
|                         | High risk (>130)                   | 2 (5.5%)                        | 0         |         |
| Triglyceride (mg/dL)    | Normal*                            | 8 (22.2%)                       | 11 (30.5%) | 0.18    |
|                         | Increased*                         | 28 (77.7%)                      | (69.4%)    |         |

*Serum triglyceride level less than the 90th percentile was considered in normal range.

Based on more than 90th percentile value for gender and age.

HDL, high-density lipoprotein; LDL, low-density lipoprotein.
correlation between lipid profile and the gender of the patients in acute phase of the disease and two months after the recovery (P ≥0.31). Distribution (mean and 95% confidence interval) of lipid profile in children with Epstein–Barr virus infection and relative atherogenesis risk categories in acute phase and two months after the recovery phase was showed in Figure 1.

Lipid profile changes (case by case) revealed that those with more impaired values in the acute phase had more changes toward normal values at the recovery that were statistically significant for all evaluated parameters of lipid profile in our study (Fig. 2).

Discussion

During infection, the changes of the lipid and lipoprotein metabolism induce anti-inflammatory effects that contribute to the host defense [7]. Besides the role of lipid transport, circulating lipoproteins participate in innate immunity by binding and detoxifying lipopolysaccharide and toxins of gram-negative, and lipoteichoic acid of Gram-positive bacteria [7]. On the other hand, the results of some studies in the literature reveal a relation between infection and atherogenesis [1, 5]. During the acute phase of the infection, the released cytokines induce a process that leads to changing the level of serum lipoproteins in a manner that resembles atherogenic process; it is usually independent of the underlying infectious disease [7, 14, 15]. It seems that the infection-induced alterations initially protect the host from the harmful effects of bacteria, viruses, and parasites. However, if prolonged, these changes in the structure and function of lipoproteins will contribute to atherogenesis [5].

Our study revealed HDL increase, two months after the recovery compared with the acute phase of the infection which was in accordance with the result of Apostolou et al. study [9].
Indeed, acute infection not only decreases the number of HDL particles and concentration of HDL cholesterol, but also alters the structure of HDL particles, leading to loss of antioxidative actions of HDL [16]. These changes resemble the changes seen in the atherogenesis [17].

The LDL level in this study was increased in the acute phase of EBV infection which was not in accordance with Nassaji et al. and Apostolou et al. studies that reported no difference and decreased level of LDL in acute phase of the infection, respectively [7, 9]. Both of these studies were designed for the adults. In addition, Nassaji et al. studied the level of LDL only in patients with acute bacterial infections. However, some studies believe that the lipid profile changes during infection in pediatric patients might be different from those of the adults [18].

The level of triglyceride increased in the acute phase of infection in our study which was compatible with Apostolou et al. study [9].

In the current study, the mean value of serum total cholesterol in the acute phase showed no significant difference with the results of the 2 months after the recovery. This result was not compatible with the findings of Apostolou et al. research [9]. The discrepancy between these two results might be possibly due to shorter follow up of our cases (2 months vs. 4 months).

The current studies reveal that other infections might also have some effects on the patients’ lipid profiles. Iscan et al. showed that the hospitalized children with infectious pharyngitis had dyslipidemia in the acute phase of the disease. The levels of serum total cholesterol, HDL, and LDL, decreased significantly in the acute phase of the disease while the serum triglyceride levels increased slightly [19].

We approached to lipid profile serum levels by determining the mean serum level and also by categorizing in normal and abnormal groups as shown in Table 2. Comparing columns of the acute phase and two months after the recovery in Table 2, the changes might not have been shown clearly and specifically because the amount of changes may not be enough to alter the risk categories. It means that despite changes, which may be clinically important, the groups may not have altered because the changes have not reached to cut off points. Our objective might be shown better by Figure 1. In addition, according to the findings of the Figure 2 those with more impaired values, had more changes toward normal values two months after the recovery.

The present study revealed that the serum lipid profile changes of the acute phase of the EBV infection in children partially improves 2 months after the recovery and residual abnormal levels in the lipid profile might be due to short-term follow up of the patients. In the study of lipid profile evaluation in patients with acute EBV infection in adults, the lipid profiles of the patients improved significantly, four months after the recovery [9]. Some other infections also reveal the evidence of the lipid profiles improvement after the recovery [5, 19]. Therefore, defined lipid profile changes could be considered as a predictor of the acute phase of the infection/inflammation, and, returning of lipid profile indices to the baseline could be interpreter of finishing infection/inflammation process. Moreover, it should be considered that evaluation of lipid profile in patients with acute EBV infection should not be performed in
the acute phase of the disease; since the results cannot be judged and might be misinterpreted; and infection and inflammation could make temporary variations in the lipid profile indices.

Anti-VCA IgG solely is not a valuable test for diagnosis of acute EBV infection. In addition, anti-VCA IgM may persist for two weeks to three months [20]. So we used not only anti-VCA IgG but positive anti-VCA IgG and/or anti-VCA IgM were enrolled in the study. It means if the time of evaluation was so early for anti-VCA IgG, to become positive then cases with positive anti-VCA IgM and negative EBNA, were included. Also, if the time of evaluation was late acute phase then cases with negative anti-VCA IgM, and positive anti-VCA IgG but negative EBNA, were enrolled.

We admit our limitations as the sample size was few and the duration of follow up of the patients was less than the same study in adults which might have affected the results. It is therefore suggested to extend this investigation with more cases and longer follow up. According to some financial and technical limitations, we only measured some indices of the lipid profile.

The severity of the disease could affect the lipid profile level. However, only one case suffered from encephalitis that might have more severe disease than the others. It is one of the limitations of this study. In addition, serum lipid profile level, before and during the acute EBV infection, should be compared to reveal that the changes are the result of EBV infection. As far as we did not have the lipid profile level of the children before the disease, we compared the lipid profile level during acute phase and two months after the recovery of EBV infection that is another limitation of this study.

In conclusion, the children with acute infectious mononucleosis might experience some changes in lipid profile in the acute phase that improves partially two months after the recovery.

Hence, the assessment of the lipid profile in convalescence stage of infectious mononucleosis might be a predictor of the recovery.

Future studies for evaluating the pattern of lipid profile changes in other infectious diseases especially bacterial and fungal infections are suggested.

Conflicts of Interest
No conflicts of interest.

References

1. Kazar J, Mongiellova V, Gajdos M, Kovacova E, Tomka J, Slyska R, Fridrich V. Anti-cytomegalovirus antibodies and other atherosclerosis risk factors in patients with cardiovascular diseases. J Geriatr Cardiol 2007;4:131-4.
2. Memon RA, Staprans I, Noor M, Holleran WM, Uchida Y, Moser AH, Feingold KR, Grunfeld C. Infection and inflammation induce LDL oxidation in vivo. Arterioscler Thromb Vasc Biol 2000;20:1536-42.
3. O’Connor S, Taylor C, Campbell LA, Epstein S, Libby P. Potential infectious etiologies of atherosclerosis: a multifactorial perspective. Emerg Infect Dis 2001;7:780–8.
4. Kanbay M, Gür G, Yücel M, Yilmaz U, Boyaciöglu S. Does eradication of Helicobacter pylori infection help normalize serum lipid and CRP levels? Dig Dis Sci 2005;50:1228-31.
5. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004;45:1169–96.
6. Van Lenten BJ, Reddy ST, Navab M, Fogelman AM. Understanding changes in high density lipoproteins during the acute phase response. Arterioscler Thromb Vasc Biol 2006;26:1687-8.
7. Nassaji M, Ghorbani R. Plasma lipid levels in patients with acute bacterial infections. Turk J Med Sci 2012;42:465-9.
8. Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 2000;181(Suppl 3):S462-72.
9. Apostolou F, Gazi IF, Logas K, Tellis CC, Tselepis AD, Liberopoulos EN, Elias M. Acute infection with Epstein–Barr virus is associated with atherogenic lipid changes. Atherosclerosis 2010;212:607–13.
10. Macsween KF, Crawford DH. Epstein-Barr virus-recent advances. Lancet Infect Dis 2003;3:131–40.
11. Azizi F, Rahmani M, Madjid M, Allahverdian S, Ghanbili J, Ghanbarian A, Hajipour R. Serum lipid levels in an Iranian population of children and adolescents: Tehran lipid and glucose study. European J Epidemiol 2001;17:281-8.
12. Anonymous. National Cholesterol Education Program:

ORCID
Shirin Sayyahfar  http://orcid.org/0000-0002-7772-8353
Amin Lavasani  http://orcid.org/0000-0002-6670-1411
Abdollah Karimi  http://orcid.org/0000-0002-8362-290X
Alireza Nateghian  http://orcid.org/0000-0001-8235-1389
highlights of the report of the expert panel on blood cholesterol levels in children and adolescents. US Department of health and human services, public health service. National institute of health, national heart, lung, and blood institute. J Am Osteopath Assoc 1992;92:380-8.

13. Tershakovec AM, Daniel D J. Disorders of lipoprotein metabolism and transport. In: Behrman RE, Kliegman RM, Jenson HB, eds. Nelson textbook of pediatrics, 17th ed. Philadelphia, PA: Saunders; 2004:445-59.

14. Khosla SN, Goyle N, Seth RK. Lipid profile in enteric fever. J Assoc Physicians India 1991;39:260-2.

15. Alvarez C, Ramos A. Lipids, lipoproteins and apoproteins in serum during infections. Clin Chem 1986;32:142-5.

16. Burger D, Dayer JM. High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation? Autoimmun Rev 2002;1:111-7.

17. Gazi IF; Elisaf MS. Effect of infection on lipid profile: focus on Epstein-Barr virus. Clin Lipidol 2010;5:607–10.

18. Volanen I, Raitakari OT, Vainionpää R, Arffman M, Aarnisalo J, Anglé S, Kallio K, Simell O. Serum lipid profiles poorly correlate with Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus seropositivity in prospectively followed-up healthy children. Arterioscler Thromb Vasc Biol 2005;25:827-32.

19. İşcan A, Yiğitoğlu R, Onaş A, Vurgun N, Ari Z, Ertan P, Sengil AZ. Should children with infection be tested for lipid, lipoprotein and apolipoprotein? Acta Paediatr Jpn 1998;40:47-51.

20. Leach CT, Sumaya CV, Harrison GJ. Epstein-Barr Virus. In: Cherry J, Demmler-Harrison G, Kaplan S, Steinbach W, Hotez P, eds. Feigin and Cherry’s textbook of pediatric infectious diseases. 7th ed. Philadelphia, PA: Elsevier Press; 2014:1992-2015.